Saturday, July 09, 2016 3:31:47 PM
Going to Round Six on July 28th, 2016 for Grant funding.
One of the other uses for Technosphere use is Inhaled oxytocin. (No mention by MannKind of their involvement but you will see a Technospere inhaler and mention by the speaker Robin Offord of Mintaka Foundation of a Industry partner.)
Watch this video. In conjunction with the bill and Melinda Gates foundation in a teaching institution in Australia
inhaled Oxytocin video link
Video showing Technosphere (mention of inhaler as being developed by an industry partner--- Must be because of confidentiality agreement no mention of MannKind)
Saving Lives at Birth web link About Round Six competition
Gold Standard Postpartum Hemorrhage Prevention to Women in Greatest Need
Organization: Monash University
Organization Location: Melbourne, Victoria, Australia
Over 300,000 women die each year due to pregnancy-related causes with hemorrhage being the leading cause. Oxytocin is the gold standard therapy to prevent postpartum hemorrhage and is recommended by the WHO to be used at every birth. Oxytocin is currently available as an injection that requires refrigeration to maintain quality and skilled healthcare workers to safely administer the product. These factors significantly limit the availability and impact of this medicine, particularly in resource poor settings. This project seeks to substantially expand access to oxytocin through the development of an affordable, simple to administer inhaled oxytocin delivery system. Using innovative technology, inhaled oxytocin is formulated as a fine powder that can withstand the climatic conditions common in tropical regions without the need for refrigeration. The product therefore removes the requirement for cold chain supply and storage, potentially allows task-shifting to lower tier healthcare and community workers and has the potential to save 146,000 lives over 8 years (www.ic2030.org). This proposal recognizes that the successful implementation of innovations in global health relies not simply on technical effectiveness but also adaption to meet the needs of the local environment to which the innovation is applied. The planned work will ensure that the product design, presentation and implementation will facilitate maximal access and uptake by end users of greatest need.
The Gates foundation competition in Washington, DC July 26 -28, 2016 with USAID and other global health partners:
In its sixth round, 50 promising finalists from nearly 650 applications will come together to compete in the final stage of the 2016 Saving Lives at Birth Grand Challenge. The finalists will gather at the DevelopmentXChange in Washington DC, from July 26-28, 2016. There, they will learn from each other, interact with potential collaborators, and meet technical advisors in a number of discussion groups and one-on-one meetings designed to facilitate further innovation and impact.
Gold Standard Postpartum Hemorrhage Prevention to Women in Greatest Need
Organization: Monash University
Organization Location: Melbourne, Victoria, Australia
Over 300,000 women die each year due to pregnancy-related causes with hemorrhage being the leading cause. Oxytocin is the gold standard therapy to prevent postpartum hemorrhage and is recommended by the WHO to be used at every birth. Oxytocin is currently available as an injection that requires refrigeration to maintain quality and skilled healthcare workers to safely administer the product. These factors significantly limit the availability and impact of this medicine, particularly in resource poor settings. This project seeks to substantially expand access to oxytocin through the development of an affordable, simple to administer inhaled oxytocin delivery system. Using innovative technology, inhaled oxytocin is formulated as a fine powder that can withstand the climatic conditions common in tropical regions without the need for refrigeration. The product therefore removes the requirement for cold chain supply and storage, potentially allows task-shifting to lower tier healthcare and community workers and has the potential to save 146,000 lives over 8 years (.ic2030). This proposal recognizes that the successful implementation of innovations in global health relies not simply on technical effectiveness but also adaption to meet the needs of the local environment to which the innovation is applied. The planned work will ensure that the product design, presentation and implementation will facilitate maximal access and uptake by end users of greatest need.
Round six will be in Washington, DC on July 26, 2016 and it seems to be open to the public.
The Gates foundation competition in conjunction with USAID and several other World Health groups in Washington, DC July 26 -28
Watch the video link -- He is using a Technosphere Inhaler. Round 6 in Washington, DC July 26-28
Robin Offord Mintaka Foundation
Round Six of this Saving Lives at Birth event.
Recent MNKD News
- MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease • GlobeNewswire Inc. • 05/06/2024 10:05:00 AM
- MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024 • GlobeNewswire Inc. • 05/01/2024 08:00:00 PM
- MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases • GlobeNewswire Inc. • 04/30/2024 10:05:00 AM
- MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease • GlobeNewswire Inc. • 04/29/2024 10:05:00 AM
- MannKind Repays Certain Debt Obligations • GlobeNewswire Inc. • 04/03/2024 10:00:00 AM
- MannKind Announces CFO Transition • GlobeNewswire Inc. • 03/26/2024 08:05:00 PM
- INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps • GlobeNewswire Inc. • 03/11/2024 10:05:00 AM
- MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8 • GlobeNewswire Inc. • 03/05/2024 11:05:00 AM
- MannKind Corporation Announces Participation at Upcoming Conferences • GlobeNewswire Inc. • 03/04/2024 06:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:05:20 PM
- MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update • GlobeNewswire Inc. • 02/27/2024 09:00:00 PM
- MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024 • GlobeNewswire Inc. • 02/20/2024 11:00:00 AM
- MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza® • GlobeNewswire Inc. • 02/15/2024 11:05:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 11:06:28 AM
- MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million • GlobeNewswire Inc. • 01/02/2024 11:05:00 AM
- MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 12/28/2023 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:15:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/16/2023 02:00:12 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/15/2023 09:09:12 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM